Sectors
HELP
Cybin D/B/A Helus Pharma
11.45
1 x 6.79
1 x 11.87
bid
ask
-
0.73
5.99%
02:08 PM
timesize
| Ytd | 39.98% | |
| 1y | 53.07% |
11.26
day range
12.19
3.76
52 week range
14.35
| Open | 11.98 | Prev Close | 12.18 | Low | 11.26 | High | 12.19 | Mkt Cap | 830.69M |
| Vol | 880.54K | Avg Vol | 1.60M | EPS | -4.06 | P/E | N/A | Forward P/E | -7.59 |
| Beta | 0.55 | Short Ratio | 1.99 | Inst. Own | 43.76% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 8.66 | 200-d Avg | 6.61 | 1yr Est | 41.51 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-12 | 2026-09 | -0.67 | N/A | N/A | N/A |
| 2026-08-14 | 2026-06 | -0.84 | -0.91 | -0.07 | -8.84% |
| 2026-06-30 | 2026-03 | -1.04 | -0.96 | 0.08 | 8.09% |
| 2026-02-13 | 2025-12 | -0.53 | -0.99 | -0.46 | -87.25% |
| 2025-11-13 | 2025-09 | -0.74 | -1.39 | -0.65 | -87.84% |
| 2025-08-13 | 2025-06 | -0.96 | -1.1 | -0.14 | -14.72% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-20 | TD Cowen | Upgrade | Buy | Buy |
| 2026-07-27 | Wells Fargo | Upgrade | Overweight | |
| 2026-07-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2026-07-01 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-04-13 | TD Cowen | Upgrade | Buy | |
| 2026-03-02 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and HLP004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company' preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluating HLP003 for the adjunctive treatment of major depressive disorder; and with Osmind for mental health treatments. The company is headquartered in Toronto, Canada.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-30 | Bartlone (Aaron Frank) | Senior Officer of Issuer | 172.65K | Exercise of rights |
| 2026-07-12 | Cavers (Gregory Joseph) | Senior Officer of Issuer | 86.77K | Acquisition or disposition in the public market |
| 2026-07-12 | Fahel (Gabriel) | Senior Officer of Issuer | 73.46K | Acquisition or disposition in the public market |
| 2026-06-30 | Froese (Grant B.) | Director of Issuer | 0.00 | Exercise of rights |
| 2026-06-30 | Glavine (Paul) | 10% Security Holder of Issuer | 2.91M | Exercise of rights |
| 2026-06-30 | Hoskins (Eric William) | Director of Issuer | 0.00 | Exercise of rights |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | Venrock Adviser, LLC | 3.85M | 53.87M | 5.27% |
| 2026-06-29 | Orbimed Advisors LLC. | 3.27M | 45.75M | 4.48% |
| 2026-06-29 | Adage Capital Partners GP L.L.C. | 3.06M | 42.79M | 4.19% |
| 2026-06-29 | Millennium Management Llc | 2.63M | 36.81M | 3.60% |
| 2026-06-29 | Rosalind Advisors, Inc. | 1.96M | 27.37M | 2.68% |
| 2026-06-29 | Sphera Funds Management Ltd. | 1.62M | 22.67M | 2.22% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 1.41M | 19.73M | 1.93% |
| 2026-07-30 | AdvisorShares Trust-AdvisorShares Psychedelics ETF | 340.44K | 4.76M | 0.47% |
| 2026-06-29 | ROYCE FUND-Royce Smaller-Companies Growth Fund | 232.00K | 3.24M | 0.32% |
| 2026-06-29 | Invesco Exch-Trd Fd. TRT II-Invesco NASDAQ Future Gen 200 ETF | 23.13K | 323.47K | 0.03% |
| 2026-06-29 | Fidelity Concord Street Trust-Fidelity Nasdaq Composite Index Fund | 14.37K | 200.99K | 0.02% |